06 August 2021 | News
Fusion Antibodies and BioTickle partnership delivers value with proprietary antibody discovery, engineering and cell line technologies
Photo Credit: Freepik
Fusion Antibodies, pre-clinical antibody discovery, and development experts, and BioTickle, their exclusive distributor in India, are providing local biopharmaceutical organizations with access to invaluable unique biopharmaceutical development capabilities.
As Dr Richard Jones, CEO of Fusion Antibodies explains, “We are proud of the support we can offer to the biotherapeutic developers in India who are working at the leading-edge of this global industry. Together with our clients, we are developing novel therapeutic candidates aimed at a range of diseases. We can also support organisations with the development of antibodies that are specifically engineered to neutralise the SARS-CoV-2 virus, which of course is one of the biggest challenges facing the world at the moment.”
Since the emergence of COVID-19, Fusion Antibodies has dedicated resources into developing a panel of unique protein antigens for use in discovery platforms. To date, the proteins have shown excellent profiles in terms of activity and scalability. Furthermore, the company has been awarded a grant from Invest Northern Ireland to expand their COVID-19 focused research to accelerate the discovery of novel therapeutic and diagnostic antibodies.
“Through BioTickle, Fusion Antibodies is well-placed to provide world-class support to Indian biopharmaceutical developers no matter their target therapeutic area, from infectious diseases to oncology,” states Richard.